Open Access10% INTRAVENOUS IMMUNOGLOBULIN GAMUNEX IN THE TREATMENT OF PRIMARY IMMUNODEFICIENCIES PATIENTS: OWN EXPERIENCE AND LITERATURE REVIEW
Author(s) -
И. Н. Смирнова,
Tatiana Kosacheva,
O V Shvetz,
S.B. Zimin,
A Yur'evna Shcherbina
Publication year - 2014
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja547
Subject(s) - medicine , primary immunodeficiency , antibody , intravenous infusions , pediatrics , immunology , disease
Intravenous immunoglobulin G preparation (IVIG) is an effective and safe therapeutic modality in the primary immunodeficiencies (PID) management. We investigated effectiveness and safety of the 10% preparation of IVIG Gamunex in treatment of 26 patients with primary immunodeficiencies at ages 8 months 17 years. Percentage of nonsevere reactions to Gamunex infusions was similar as to other 5% IVIG preparations (2,9 vs 2,8%). Average time of infusion was reduced from 88 minutes for 5% IVIG to 67 minutes for Gamunex. Average trough IgG level after Gamunex infusions was sufficient (6,8 g/l) and resulted in the absence of significant infectious episodes in PID patients during the study period. Our study demonstrated good efficacy and safety profile of Gamunex.